These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 31011203)

  • 1. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.
    Niewczas MA; Pavkov ME; Skupien J; Smiles A; Md Dom ZI; Wilson JM; Park J; Nair V; Schlafly A; Saulnier PJ; Satake E; Simeone CA; Shah H; Qiu C; Looker HC; Fiorina P; Ware CF; Sun JK; Doria A; Kretzler M; Susztak K; Duffin KL; Nelson RG; Krolewski AS
    Nat Med; 2019 May; 25(5):805-813. PubMed ID: 31011203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes.
    Satake E; Saulnier PJ; Kobayashi H; Gupta MK; Looker HC; Wilson JM; Md Dom ZI; Ihara K; O'Neil K; Krolewski B; Pipino C; Pavkov ME; Nair V; Bitzer M; Niewczas MA; Kretzler M; Mauer M; Doria A; Najafian B; Kulkarni RN; Duffin KL; Pezzolesi MG; Kahn CR; Nelson RG; Krolewski AS
    J Am Soc Nephrol; 2021 Sep; 32(9):2331-2351. PubMed ID: 34140396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters.
    Bodlaj G; Berg J; Pichler R; Sailer T; Biesenbach G
    J Nephrol; 2004; 17(1):112-7. PubMed ID: 15151267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.
    Yamanouchi M; Skupien J; Niewczas MA; Smiles AM; Doria A; Stanton RC; Galecki AT; Duffin KL; Pullen N; Breyer MD; Bonventre JV; Warram JH; Krolewski AS
    Kidney Int; 2017 Jul; 92(1):258-266. PubMed ID: 28396115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added value of soluble tumor necrosis factor-α receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes.
    Forsblom C; Moran J; Harjutsalo V; Loughman T; Wadén J; Tolonen N; Thorn L; Saraheimo M; Gordin D; Groop PH; Thomas MC;
    Diabetes Care; 2014 Aug; 37(8):2334-42. PubMed ID: 24879837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P
    Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease.
    Niewczas MA; Mathew AV; Croall S; Byun J; Major M; Sabisetti VS; Smiles A; Bonventre JV; Pennathur S; Krolewski AS
    Diabetes Care; 2017 Mar; 40(3):383-390. PubMed ID: 28087576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of circulating inflammatory protein in the development of diabetic renal complications: proteome-wide Mendelian randomization and colocalization analyses.
    Liu W; Zhang J; Zhang D; Zhang L
    Front Endocrinol (Lausanne); 2024; 15():1406442. PubMed ID: 39040677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1.
    Lee JE; Gohda T; Walker WH; Skupien J; Smiles AM; Holak RR; Jeong J; McDonnell KP; Krolewski AS; Niewczas MA
    PLoS One; 2013; 8(3):e58007. PubMed ID: 23526964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients.
    Covic AM; Schelling JR; Constantiner M; Iyengar SK; Sedor JR
    Kidney Int; 2000 Oct; 58(4):1742-50. PubMed ID: 11012908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease.
    Murakoshi M; Gohda T; Suzuki Y
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes.
    Velho G; Ragot S; Mohammedi K; Gand E; Fraty M; Fumeron F; Saulnier PJ; Bellili-Munoz N; Bouby N; Potier L; Alhenc-Gelas F; Marre M; Hadjadj S; Roussel R
    Diabetes; 2015 Sep; 64(9):3262-72. PubMed ID: 25948679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort.
    Saulnier PJ; Gand E; Ragot S; Ducrocq G; Halimi JM; Hulin-Delmotte C; Llaty P; Montaigne D; Rigalleau V; Roussel R; Velho G; Sosner P; Zaoui P; Hadjadj S;
    Diabetes Care; 2014 May; 37(5):1425-31. PubMed ID: 24623026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes.
    Saulnier PJ; Dieter BP; Tanamas SK; McPherson SM; Wheelock KM; Knowler WC; Looker HC; Meek RL; Nelson RG; Tuttle KR
    Am J Nephrol; 2017; 46(4):276-284. PubMed ID: 28934744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy.
    Gordin D; Shah H; Shinjo T; St-Louis R; Qi W; Park K; Paniagua SM; Pober DM; Wu IH; Bahnam V; Brissett MJ; Tinsley LJ; Dreyfuss JM; Pan H; Dong Y; Niewczas MA; Amenta P; Sadowski T; Kannt A; Keenan HA; King GL
    Diabetes Care; 2019 Jul; 42(7):1263-1273. PubMed ID: 31076418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM.
    Kimura H; Suzuki Y; Gejyo F; Karasawa R; Miyazaki R; Suzuki S; Arakawa M
    Am J Kidney Dis; 1998 Apr; 31(4):666-73. PubMed ID: 9531184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study.
    Smyth LJ; Kilner J; Nair V; Liu H; Brennan E; Kerr K; Sandholm N; Cole J; Dahlström E; Syreeni A; Salem RM; Nelson RG; Looker HC; Wooster C; Anderson K; McKay GJ; Kee F; Young I; Andrews D; Forsblom C; Hirschhorn JN; Godson C; Groop PH; Maxwell AP; Susztak K; Kretzler M; Florez JC; McKnight AJ
    Clin Epigenetics; 2021 May; 13(1):99. PubMed ID: 33933144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease.
    Yamanouchi M; Mori M; Hoshino J; Kinowaki K; Fujii T; Ohashi K; Furuichi K; Wada T; Ubara Y
    BMJ Open Diabetes Res Care; 2019; 7(1):e000726. PubMed ID: 31798893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.
    Kobayashi H; Looker HC; Satake E; Saulnier PJ; Md Dom ZI; O'Neil K; Ihara K; Krolewski B; Galecki AT; Niewczas MA; Wilson JM; Doria A; Duffin KL; Nelson RG; Krolewski AS
    Kidney Int; 2022 Aug; 102(2):370-381. PubMed ID: 35618095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.